1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Diagnostic Imaging Market Trends
  5. > Advances in Molecular Imaging: A market coming of age

Advances in Molecular Imaging: A market coming of age

  • April 2013
  • -
  • Espicom Business Intelligence
  • -
  • 292 pages

Since 2010, the market has seen stronger growth, helped by demand in under-penetrated markets, the adoption of newer-generation hybrid imaging technologies such as PET/CT and a move towards the use of PET from SPECT, necessitating the purchase of new PET systems.

The short-lived positron-emitting isotopes used in PET imaging are generally produced in a cyclotron and then synthesised on-site before patient administration. Although not requiring the use of a nuclear reactor, this limits the use of PET imaging to centres with access to a cyclotron and synthesis equipment. Therefore, a major development is the recent availability of smaller and cheaper cyclotrons which are designed to produce C-11 and F-18 isotopes economically and on-demand, without the need for radiochemistry or PET accelerator expertise.

The drive towards PET has been additionally boosted by advancement in the diagnosis of Alzheimer’s disease and the approval of Avid Radiopharmaceuticals’ Amyvid (florbetapir F-18 injection). Avid (owned by Eli Lilly) is the first company to achieve approval for a diagnostic PET tracer which estimates beta amyloid neuritic plaque density in adults with cognitive impairment. This is likely to become a busy marketplace with GE, Piramel and Navidea developing late-stage products whilst the focus of new research is targeting the tau proteins.

With this report you will:

Know the state of the molecular imaging market and recent advances in Alzheimer’s diagnosis
Establish the future market growth with 5-year value forecasts
Know the clinical and regulatory challenges facing the sector
Assess the companies that are developing hybrid technologies
Review the challenges facing producers of radiopharmaceuticals and the research which is seeking alternative paths
Know why PET is outpacing SPECT and the advantages it brings
Appreciate the regulatory hurdles affecting radiopharmaceutical producers in the US
Understand the changing competitive landscape and market positioning of new entrants
The MI market fundamentals remain solid and there are strong opportunities for growth within the industry. These are being driven by continued innovation and new product development, beneficial demographics, an ageing installed base of imaging equipment in the developed markets of the US and Europe, and the increasing adoption of MI technologies in emerging markets.


In particular, the increasing incidence of cancer, cardiovascular and neurological diseases means that demand for faster and more accurate diagnosis, as well as drug development and pre-clinical study efforts, will continue to accelerate in coming years. In addition, MI technologies will become more widely adopted as clinical evidence is established as to their benefits, and new technological innovations continue to be brought to market, particularly related to the MI of cancer and neurological diseases such as Alzheimer’s and Parkinson’s.

In addition, the current lack of penetration for nuclear and molecular imaging in emerging economies is driving demand, where new facilities are being set up and lower-cost systems are in demand.

Challenges to overcome
The short and mid-term prospects for MI are to a large extent dependant on the pace of economic recovery, which will affect the ability of smaller companies to obtain financing and future healthcare budgets, particularly in Europe. In addition, uncertainties currently exist surrounding Mo-99 supply, the impact of the US medical device excise tax, new regulatory hurdles for radiopharmaceuticals in the US and whether beta amyloid PET imaging (and related technologies) will be sufficiently reimbursed to facilitate their widespread use.

A changing competitive landscape
Currently, the key players in the MI market include medical diagnostic imaging equipment manufacturers such as Philips, Siemens and GE; radiopharmaceutical and imaging agent companies such as GE, Bracco, Covidien, IBA Molecular and Lantheus Medical Imaging; and companies that operate radiopharmacies such as Cardinal Health, Triad Isotopes and Siemens. The landscape is shifting and, despite pharmaceutical companies such as BMS and Bayer leaving the MI market, others have been keen to enter.


Piramal Group has gained a strong position in MI. The company now owns the intellectual property and development, marketing and distribution rights for Bayer's lead compound, florbetaben, which is seen as a promised imaging agent for AD. Through the Bayer transaction, Piramal now also owns other clinical and pre-clinical agents that are in development for cardiology and oncology imaging.
Progenics Pharmaceuticals is focusing on developing therapeutic radiopharmaceuticals and targeted MI agents for oncology, through its acquisition of Molecular Insight Pharmaceuticals.

And it is not just Pharma companies:

PerkinElmer has acquired VisEn Medical and Caliper Lifesciences, who’s in vivo and in vitro diagnostics are used in pre-clinical drug development work.
Samsung has strengthened its medical imaging business with the acquisition, in January 2013, of NeuroLogica. Although mainly focused on portable CT scanners, NeuroLogica also offers the inSPira HD portable SPECT system.

The report covers companies active in the major MI sectors

Nuclear Imaging
Near infrared or optical imaging
Ultrasound
MRI
MRI/PET
MRI/SPECT
Tracers and Radiopharmaceuticals

This report answers key business questions...

What alternatives are being considered to mitigate the ongoing supply issues with the Molybdenum-99 isotope?
In which therapy sectors are MI technologies playing a key diagnostic role and with what success?
What collaborative role are academic institutions playing in MI development?
Which companies are most advanced in introducing hybrid imaging systems?
For which tracing agent did Navidea receive FDA approval in March 2013?
Which 2 Spanish companies did Advanced Accelerator Applications acquire in January 2013?
What development in 2012 strengthened Bruker’s position in the pre-clinical imaging sector?
What developments are helping GE maintain its leading position in the molecular imaging sector?


About the Author
This report has been researched and written by experienced and independent medical market analyst Joanne Maddox. For over 13 years she has played a pivotal role in tracking trends in medical device and equipment markets and companies. A former editor of Medical Device Companies Analysis she has also written Medical IT: Understanding the major players and products; All Change in the Advanced Wound Care Market and Point of Care Diagnostics: Players, Products and Prospects.

About the Publisher
Espicom Business Intelligence is a leading provider of specialist health industry market information. Based in the UK and with over 30 years of experience, the company produces a broad range of business and therapy titles and is uniquely placed to publish this report. Espicom is part of Business Monitor International.

Just some of the information services particularly relevant to this study include:

Medical Imaging News
Medical Imaging News is a key resource for every executive working in - or analysing - this key industry sector. Medical Imaging News takes the hard work and effort out of staying in touch with the companies, products, alliances and research that are shaping global imaging markets. If you need to stay in touch with the latest twists and turns then this daily-updated online information service is essential. Visit www.espicom.com/min for more details.

Point of Care Diagnostics: Players, Products & Prospects
A major 4-volume report published Spring 2013, providing:
• Unique 5-year sales forecasts for major POC diagnostic sectors
• A comprehensive examination of all diagnostic sectors and the products
• Detailed competitive evaluation covering companies active in each area

Available in PDF or web.

Table Of Contents

Advances in Molecular Imaging: A market coming of age
Table of Contents

EXECUTIVE SUMMARY 1
INTRODUCTION 1
Applications of MI 2
Neurological Disease 2
Oncology 2
Cardiovascular Disease 3
MI for use in LifeSciences and the Pharmaceutical Industry 3
MI Modalities 4
Hybrid MRI/PET Imaging 5
Hybrid MRI/SPECT Imaging 7
Tracers and Radiopharmaceuticals 7
COMPETITIVE LANDSCAPE 8
New Market Entrants 9
Market Consolidation 10
Collaborative Development Efforts 11
Barriers to Market Entry and Challenges for Smaller Companies 12
CURRENT MARKET DYNAMICS 13
Nuclear Imaging Adoption 13
Market Insight 13
Fig 1: Diagnostic Imaging Systems Market by Modality, 2012 14
Fig 2: Medical Imaging Market, 2005-2012 (US$ billion)* 15
Fig 3: Nuclear Imaging Equipment Market, 2007-2012 (US$ billion)* 16
Fig 4: Molecular Imaging Market by End-Use Product Type, 2010 16
Molybdenum-99 Isotope Supply Issues 16
Recent Developments in the PET Market 21
Alzheimer's Disease PET Imaging 22
Lymphoseek Lymph Node Imaging 26
PET Regulatory Approval Issues 26
Improved Optical Imaging Techniques 27
MARKET OUTLOOK 28
Molecular Imaging: Market Drivers, Restraints and Future Opportunities 28
Fig 5: Nuclear Imaging Equipment Market, 2012-2017E (US$ million)* 29
Fig 6: Pre-Clinical Imaging Systems Market, 2012-2017E (US$ million) 29
Fig 7: Radiopharmaceuticals Market, 2012-2017E (US$ million) 30
Fig 8: Molecular Imaging End-Use Products Market, 2012-2017E (US$ million)* 30
MOLECULAR IMAGING COMPANIES 31
ABT MOLECULAR IMAGING 31
“Dose on Demand” Biomarker Generator 31
ABX 33
ADVANCED ACCELERATOR APPLICATIONS 34
Recent Events 34
Mergers and Acquisitions 35
Products 35
Research and Development: Annexin V-128 36
Current Alliances 36
UWRC SPÓ?KA Z OGRANICZON? ODPOWIEDZIALNO?CI?, University of Warsaw 36
GE Healthcare 37
Institut Curie 37
IASON GmbH 37
European Molecular Imaging Manufacturers Association 37
Bracco 37
Financial Performance 37
ADVANCED CYCLOTRON SYSTEMS 38
Recent Events 38
Products 38
TR 24 Cyclotrons 38
TR 30 Cyclotrons 39
TR PET Cyclotrons 39
CycloTec RandD Programme 39
Current Alliances 40
TRIUMF 40
GE Healthcare 41
ADVANCED MEDICAL ISOTOPE 42
Products in Development 42
US Production of Molybdenum-99 43
Alliance with GSG International 44
Financial Performance 44
AMIC - Operating Results, 2007-2011 (US$ thousand) 45
Fig 9: AMIC - Revenue by Type, 2011 45
Latest Results 45
AFFIBODY 47
ABY-025 HER2-Binding Affibody Imaging Agent 47
Clinical Study Results 48
Alliance with GE Healthcare 49
AGENIX 50
ThromboView 50
Pulmonary Embolism Application 50
Deep Vein Thrombosis 51
ALSERES PHARMACEUTICALS 52
Altropane 52
Clinical Study Results 52
Navidea Biopharmaceuticals Licence Agreement 53
ANTICANCER 54
Current Alliances 54
UVP 54
Caliper Life Sciences (PerkinElmer) 55
INDEC Systems 55
Olympus 55
APOSENSE 56
[18F]-ML-10 and EarliTest 56
Clinical Trial Results 57
Current Agreements 57
IBA 57
Sigma-Aldrich 58
ART ADVANCED RESEARCH TECHNOLOGIES 59
ART: Recent Events 59
Products 59
Optix MX3 60
SoftScan Optical Breast Imaging System 60
Fenestra Contrast Agents 61
ASTELLAS PHARMA 62
Lexiscan (regadenoson) 62
Clinical Trial Results 63
Adenoscan (adenosine injection) 63
Cardiac Imaging Revenue 64
Fig 10: Astellas Pharma's Cardiac Imaging Sales, Fiscal 2008-2011 (US$ million) 64
AVID RADIOPHARMACEUTICALS (ELI LILLY) 65
Amyvid (florbetapir F 18 injection) 65
Clinical Study Results 66
Products in Development 67
18F-AV-133 67
Current Alliances 67
Cardinal Health 67
PETNET Solutions (Siemens) 67
Piramal Imaging 67
BIOSCAN 68
Pre-Clinical Imaging Products 68
BioFLECT 68
NanoSPECT/CT and NanoPET/CT 69
HiSPECT 70
IMAPPI Consortium 70
BIOSPACE LAB 71
Recent Key Events 71
Products 71
Photon Imager Systems 71
Beta Imager 72
Current Alliances72
Centre for Advanced Biomedical Imaging at University College London 72
ImaBio Group 73
BRACCO 74
Products 74
CardioGen-82 74
Research and Development 75
Ultrasound MI Contrast Agents 76
Current Alliances 76
Rete Ventures 76
Nordion76
Advanced Accelerator Applications (AAA) 76
ImaRx Therapeutics 77
VisualSonics 77
BRUKER 78
Recent Key Events 78
Products 79
Pre-Clinical MRI 79
Albira PET/SPECT/CT System 81
In Vivo Optical Imaging Solutions 81
Current Alliances 82
Philips 82
Aspect Imaging 83
University of York, UK 83
Iseult Programme 83
Siemens 84
BV CYCLOTRON VU 85
Products 85
Current Alliances 85
IBA Group 85
Alliance with VU University Medical Centre 85
CARDINAL HEALTH 86
Recent Key Events 86
Imaging Facilities 86
Products 87
Cardiac Imaging Agents 87
Current Alliances and Collaborations 88
Lantheus Medical Imaging 88
Eli Lilly 88
ProVision Healthcare 88
University of Washington 88
American College of Radiology Imaging Network 88
Ohio Third Frontier and Ohio State University 89
Eckert and Ziegler 89
GE Healthcare 89
Navidea Biopharmaceuticals 90
CELLPOINT 91
Recent Key Events 91
EC Technology 91
99mTc-EC-G for Oncology 92
99mTc-EC-G for Cardiology92
99mTc-EC-Metronidazole for Stroke and Tumour Hypoxia 92
N4 Technology 93
Dual Agent Technology 93
Beta Cell Technology 93
Current Alliances 93
Hanmi Pharmaceutical and HYUN IMC 93
MJM Productos Farmaceuticos e de Radioprotecao 94
Philips Healthcare 94
M D Anderson Cancer Center 94
COVIDIEN (MALLINCKRODT) 95
Recent Key Events 95
Mallinckrodt PLC 95
Products 96
Radiopharmaceuticals 96
Current Alliances 97
Rapidscan Pharma Solutions 97
Positron 98
Institute of Atomic Energy, Poland 98
Financial Performance 98
Fig 11: Covidien's Imaging Sales, 2006-2012 (US$ million) 99
Mallinckrodt in Fiscal 2012 99
Mallinckrodt plc - Revenue by Division, 2010-2012 (US$ million) 99
Fig 12: Mallinckrodt plc - Revenue by Division, 2012 100
Mallinckrodt Global Medical Imaging - Revenue by Geographic Region, 2010-2012 (US$ million) 100
Fig 13: Mallinckrodt Global Medical Imaging - Revenue by Geographic Region, 2012 100
Mallinckrodt Global Medical Imaging - Revenue by Key Product, 2010-2012 (US$ million) 101
Fig 14: Mallinckrodt Global Medical Imaging - Revenue by Key Product, 2012 101
Latest Results 101
CYCLOPHARMA 102
DIGIRAD 103
Recent Key Events 103
Products 103
ergo 103
Cardius XPO Series 104
Alliance with Dilon Diagnostics 105
Financial Performance 105
Digirad - Operating Results, 2008-2012 (US$ million) 105
Fig 15: Digirad - Revenue by Division, 2012 106
DILON DIAGNOSTICS 107
Recent Key Events 107
Dilon 6800 Gamma Camera 107
Dilon 6800 Acella 108
GammaL?c 108
declipseSPECT 108
Recent BSGI Clinical Trial Results 109
Current Alliances and Contracts 111
SurgicEye 111
PenRad 111
Digirad 111
Terason Ultrasound 111
ECKERT and ZIEGLER 112
Recent Key Events 112
Products and Services 113
Isotope Products 113
Radiopharma Products 113
Contracts and Alliances 114
Euromedic International 114
ZAG Zyklotron 114
Polish Medical University of Gdansk 114
Cardinal Health 114
Financial Performance 114
ECZACIBA?I-MONROL NUCLEAR PRODUCTS 115
Mergers and Acquisitions 115
ERIGAL 116
FLUOROPHARMA MEDICAL 117
Product Pipeline 117
CardioPET 117
BFPET 118
VasoPET 118
AZPET 118
GAMMA MEDICA-IDEAS 119
LumaGEM Molecular Breast Imaging System 119
Clinical Study Results 120
Pre-Clinical Imaging 121
GE HEALTHCARE 123
Recent Key Events 123
Products 124
PET/CT +MR Imaging Platform 124
SPECT Systems 124
SPECT/CT Systems 125
Alcyone Technology Nuclear Imaging Products 126
Ventri Nuclear Cardiology System 127
PET/CT 127
PET Radiopharmacy Products 129
Nuclear and Molecular Imaging Agents 130
Research and Development 132
Research Projects 133
Research Collaborations 137
Distribution and Other Agreements 141
Advanced Accelerator Applications (AAA) 141
Rapidscan Pharma Solutions 141
Nihon Medi-Physics Joint Venture with Sumitomo Chemical 141
Lantheus Medical Imaging 142
Financial Performance 142
GE Healthcare Operating Results, 2007-2012 (US$ million) 142
Fig 16: GE Healthcare - Revenue by Product Area, 2011* 142
GUERBET 143
Research and Development 143
Current Alliances and Collaborations 143
Gallimed Project - Nordion and Cyceron 143
IMAkinib 144
Iseult Programme 144
Other Projects 145
HAMAMATSU PHOTONICS 146
Products 146
Animal PET Scanner SHR-7700 146
Research and Development 146
Reflectance Diffuse Optical Tomography 146
IBA GROUP 148
Recent Key Events 149
MI Products and Services 149
IBA Molecular - Radiopharmaceuticals 149
IBA RadioPharma Solutions 150
Research and Development 151
Current Alliances and Contracts 152
Piramal Imaging 152
Novation 152
KeyMarker Consortium 152
Servicio Andaluz de Salud, Spain 152
Dehnel - Particle Accelerator Components and Engineering 153
CEA, France, and IRE, Belgium 153
Bio Molecular Industries 153
Aposense 153
BV Cyclotron VU 153
Hae Dong Co Ltd 154
Lantheus Medical Imaging 154
Wilex 154
Financial Performance 155
IMAGINAB 156
Recent Key Events 156
Grants and Financing 157
Research Projects 157
Current Alliances and Contracts 158
Oxford Biomedica 158
H Lundbeck 158
MacroGenics 158
Singapore Radiopharmaceuticals 159
BZL Biologics 159
GE Imanet 160
KeyMarker Consortium 160
University of California, Los Angeles 160
Dainippon Seiki 160
Eurogentec 161
Singapore's Agency for Science, Technology and Research 161
GlaxoSmithKline 161
IMAGING DIAGNOSTIC SYSTEMS 162
CTLM System 162
FDA Approval Application 162
Fluorescence and Molecular Imaging 163
Laser Imager for Lab Animals (LILA) 163
Financial Performance 164
IDSI - Operating Results, 2008-2012 (US$) 164
Latest Results 164
IMMUNOMEDICS 165
LeukoScan 165
Research and Development 165
TF2 for Colorectal Cancer Imaging and Radioimmunotherapy 165
Peptides for Imaging 166
INDEC SYSTEMS 169
INTRAMEDICAL IMAGING 170
JAZZ PHARMACEUTICALS 171
ProstaScint 171
Clinical Study Results 172
JUBILANT DRAXIMAGE 173
Products 173
Ruby-Fill Sr-82/Rb-82 Generator and Rubidium Elution System 174
DRAXIMAGE Sestamibi 174
Research and Development 174
Current Alliances 174
Positron 174
LANTHEUS MEDICAL IMAGING 176
Recent Key Events 176
Products 177
TechneLite (Technetium Tc99m Generator) and LEU TechneLite 177
ABLAVAR (Gadofosveset Trisodium) 177
Cardiolite 178
Neurolite 179
DEFINITY, Neurolite and Cardiolite Supply Issues 179
Research and Development 180
Flurpiridaz F 18 180
LMI 1195 for Cardiac PET Imaging 180
BMS 753951 181
Current Alliances and Contracts 181
Institute for Radioelements, Belgium 181
FUJIFILM RI Pharma 182
Nordion 182
NTP Radioisotopes 182
Jubilant HollisterStier 182
Ben Venue Laboratories 182
Premier Purchasing Partners 183
Cardiolite and TechneLite Distribution Agreements 183
Australian Nuclear Science and Technology Organisation 183
IBA Group 183
Financial Performance 184
Lantheus Medical Imaging - Operating Results, 2007-2011 (US$ million) 184
Lantheus Medical Imaging - Sales by Key Product Line, 2008-2011 (US$ million) 184
Fig 17: Lantheus Medical Imaging - Revenue by Product Line, 2011 185
Latest Results 185
LIGHTOOLS RESEARCH 186
MI Products 186
Pan-A-See-Ya Panorama 186
Macro-Illumination Imaging System 186
Macro-Imaging System Plus 186
MEDISO MEDICAL IMAGING SYSTEMS 187
Recent Key Events 187
nanoScan Pre-Clinical Imaging 187
nanoScan SPECT/MRI 187
nanoScan PM PET/MRI 188
Clinical Imaging 188
AnyScan SPECT-CT-PET 188
Nucline Gamma Cameras 189
Current Alliances and Collaborations 189
SPADnet 189
INSERT 190
Absolute Imaging Solutions 190
Aspect Imaging 190
MILABS 191
Products 191
VECTor 191
Quick-Start SPECT (U-SPECTQS) 191
U-SPECT-II/CT 191
U-SPECT Scanners 191
Current Alliances 192
Mid-Atlantic Imaging Services 192
NAVIDEA BIOPHARMACEUTICALS 193
Recent Key Events 193
Lymphoseek 194
Clinical Study Results 194
Research and Development 195
Expanded Indications for Lymphoseek 195
RIGScan 196
NAV5001 [123I]-E-IACFT Injection (Altropane) 197
NAV4694 198
Current Alliances and Licences 199
Alseres Pharmaceuticals 199
AstraZeneca 199
Dow Chemical Company 200
Laureate Pharma 200
Cardinal Health 200
University of California, San Diego 200
NAVISCAN 201
Recent Key Events 201
Positron Emission Mammography Scanner201
PEM Clinical Study Results 202
Stereo Navigator 203
MIMviewer PEM 204
Current Alliances 204
Ledford Medical Electronics 204
Chindex Medical 204
Tecnologie Avanzate 204
Nuclear Medicine Distributors 204
SCETI 204
Hae Dong Co Ltd 205
MIMVista 205
NEUROLOGICA (SAMSUNG ELECTRONICS) 206
NORDION 207
Recent Key Events 208
Products 208
Medical Isotopes 208
Current Alliances 210
The Open Joint Stock Company “Isotope” and Research Institute of Atomic Reactors, Russia 210
Lantheus Medical Imaging 210
Gallimed Project - Guerbet and Cyceron 210
Bracco 211
TRIUMF and the University of British Columbia 211
University of Ottawa Heart Institute 211
Financial Performance 212
Nordion - Results from Continuing Operations, 2010-2012 (US$ million) 212
Fig 18: Nordion - Percentage of Revenue by Segment, 2012 213
Nordion - Sales and Earning by Segment, 2010-2012 (US$ million) 213
Medical Isotope Segment Results 213
Nordion - Medical Isotope Sales by Product Line, 2010-2012 (US$ million) 214
Fig 19: Nordion - Percentage of Medical Isotope Revenue by Product Line, 2012 214
Latest Results and 2013 Outlook 214
NOVELOS THERAPEUTICS 216
124I-CLR1404 (LIGHT) 216
CLR1502 (GLOW2) 217
NUVIEW LIFE SCIENCES 218
Alliance with Thomas Jefferson University 218
VPAC1 For Imaging Prostate Cancer 218
NLS-VPAC For Imaging Breast Cancer 219
NLS-VPAC1 Labelled with Ga-68 219
NVLS/FXA-18 For Cardiovascular Disease 219
ONCOVISION 220
Albira PET/SPECT/CT System 220
Mammi Breast PET Imaging System 220
PERKINELMER 221
Recent Key Events 222
Fluorescence Molecular Tomography Imaging Systems 222
Multispecies Imaging Module 223
Imaging Agents 223
HER2Sense 225
Caliper Life Sciences' Pre-Clinical Imaging Systems 226
IVIS Imaging Systems 226
Quantum FX MicroCT System 226
Living Image Multi Modality Software Module and the Mouse Imaging Shuttle 227
Maestro MI Systems 227
Current Alliances 228
MosaMedix 228
DuPont 228
AntiCancer 228
Merck 229
Stanford University 229
Massachusetts General Hospital 229
PHARMALUCENCE 230
MI Products 230
Sulfur Colloid Injection 230
PHILIPS HEALTHCARE 232
Recent Key Events 232
Nuclear Medicine Products 232
Ingenuity TF PET/MR 233
PET/CT 233
SPECT/CT Systems 235
BrightView SPECT 235
Nuclear Gamma Cameras 235
IntelliSpace Portal 236
Extended Brilliance Workspace 236
Pre-Clinical Imaging 236
Imalytics Workspace 236
Research and Development 237
High Tech Campus 237
Molecular Imaging RandD Projects 237
Research Alliances 240
Distribution and Licensing Agreements 241
ROSATOM 241
Bioscan 241
Sun MicroSystems 241
Financial Performance 242
Philips Healthcare: Operating Results, 2008-2012 (EUR million) 242
Fig 20: Philips Healthcare - Revenue by Segment, 2012 243
Fig 21: Philips Healthcare - Revenue by Region, 2012 243
PIRAMAL ENTERPRISES 244
Research and Development 244
Florbetaben PET Tracer 244
Ga68-Bombesin for Prostate Cancer PET Imaging 245
F-18-Labelled Bombesin Analogue for Imaging Prostate Cancer 245
Al18F-1 for Prostate Cancer Imaging 246
FSPG for Tumour Imaging 246
L-5-F-18-ethoxy-Tryptophan for Tumour-Specific Imaging 247
Current Alliances 248
Ion Bean Applications 248
POSITRON 249
Recent Key Events 250
Products and Services 250
PET Products 250
PosiRx Radiopharmaceutical System 251
Tech-Assist 251
Current Alliances and Contracts 252
Jubilant DraxImage 252
Institute of Nuclear Research, Troitsk, Russia 252
Amerinet 252
ARRONAX Cyclotron Facility, France 252
Covidien 252
Financial Performance 253
Positron - Operating Results, 2007-2011 (US$ thousand) 253
Latest Results 253
PROGENICS PHARMACEUTICALS 254
Recent Key Events 254
Research and Development 254
99mTc-MIP-1404 255
PROPORTIONAL TECHNOLOGIES 257
Cu-62 Micro-generator 257
Products in Development 257
PET Camera for Breast Imaging 258
PET Camera for Small Animal Studies 258
SCINTOMICS 259
Products 259
Hotbox-III (HB-III) 259
GallElut 259
GRP Modules 259
?-ICR 259
InViala 260
SEDECAL 261
SuperArgus Pre-Clinical MI Products 261
SENO MEDICAL INSTRUMENTS 262
SHIMADZU263
MI Products 263
PET Systems 263
PET/CT Systems 263
Clairvivo Pre-Clinical PET System 263
Research Agreement with the National Cancer Center, Tokyo, Japan 264
SIEMENS HEALTHCARE 265
Recent Key Events 265
Molecular Imaging and PET Products 265
Biograph mMR MRI-PET System 266
PET/CT 266
SPECT and SPECT/CT Systems 268
MI Workstations and Software 269
Pre-Clinical Imaging 270
Biomarkers 271
RandD Activities 273
Siemens Molecular Imaging Biomarker Research 273
Research Agreements 275
Supply, Distribution and Licensing Agreements 276
Avid Radiopharmaceuticals (Eli Lilly) 276
Cleveland Clinic 277
Financial Performance 277
Fig 22: Siemens Healthcare: Sales by Location of Customer, 2012 277
Latest Results 277
SOFIE BIOSCIENCES 278
Genisys4 278
18F-FAC Probes 279
ELIXYS 279
SPECTRUM DYNAMICS 280
D-SPECT Cardiac Imaging System 280
TRIAD ISOTOPES 281
ULTRASPECT 282
UNITED PHARMACY PARTNERS 284
VISUALSONICS (FUJIFILM SONOSITE) 285
Recent Key Events 285
Products 285
Vevo LAZR Photoacoustic Imaging System 285
Vevo 2100 286
Vevo 770 286
MicroMarker Contrast Agent Kits 287
Current Alliances 287
Seno Medical Instruments 287
Bracco 287
University of Virginia 287
WILEX 288
Redectane 288
Alliance with IBA Group 289
APPENDICES 290
APPENDIX 1 - LIST OF ABBREVIATIONS 290
APPENDIX 2 - REPORT METHODOLOGY 291

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Diagnostic Imaging Market: Future Horizons and Growth Strategies--Business Assessments of Leading Suppliers

Global Diagnostic Imaging Market: Future Horizons and Growth Strategies--Business Assessments of Leading Suppliers

  • $ 14500
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $14,500.  Individual company assessments $2,450.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...

Ultrasound Market: Future Horizons and Growth Strategies--Business Assessments of Leading Suppliers--M&A, Technological Capabilities, Marketing Tactics, Joint Ventures, Strategic Directions

Ultrasound Market: Future Horizons and Growth Strategies--Business Assessments of Leading Suppliers--M&A, Technological Capabilities, Marketing Tactics, Joint Ventures, Strategic Directions

  • $ 12500
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $12,500.  Individual company assessments $1,850.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...

Global Ultrasound Market: Future Horizons and Growth Strategies--Business Assessments of Leading Suppliers

Global Ultrasound Market: Future Horizons and Growth Strategies--Business Assessments of Leading Suppliers

  • $ 12500
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $12,500.  Individual company assessments $1,850.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.